Sens. Pat Roberts and Kay Hagan introduce legislation to expand MTM access
WASHINGTON — U.S. Senators Pat Roberts, R-Kan. and Kay Hagan, D-N.C. on Thursday introduced legislation written to lower healthcare costs by helping more seniors better manage their prescriptions. The Medication Therapy Management Empowerment Act will allow seniors with any high-cost chronic illness to review all their medication and develop a plan of action with a pharmacist.
“Expanding this already successful program is a commonsense, fiscally responsible way to improve seniors’ health and reduce preventable trips to the hospital,” Hagan said. “MTM programs save lives and have already saved tens of millions of dollars in North Carolina alone. I urge my colleagues to join me and Senator Roberts to pass this bipartisan bill that will keep our seniors healthy and reduce healthcare costs.”
“We have recognized the value of pharmacists in the health system for many years. They are especially valuable for our Kansas communities, and can sometimes be the only health provider in our rural towns.” Roberts added. “MTM is an important tool in the pharmacists tool box for many patients but which can be critical for those suffering from chronic conditions."
Similar legislation was introduced in the House by Rep. Cathy McMorris Rodgers, R-Wash. last week. Both the National Association of Chain Drug Stores and the National Community Pharmacists Association are fully behind the bill, the associations stated.
MTM involves pharmacists working with patients to review and monitor their medication plan to maximize its effectiveness and avoid potential health problems, ultimately helping to reduce costs in the long run. With approximately 1.5 million preventable adverse drug effects occurring every year as a result of medication errors, medication therapy programs can greatly improve patient safety, noted the NCPA in a press release issued Thursday evening. "For many Medicare patients, the challenges of coping with chronic conditions require an expert’s consultation, and pharmacists are clinically-trained in helping ensure their patients are getting the best possible results for their health," noted NCPA CEO Douglas Hoey.
In a separate release, NACDS added that only 50% of patients take their medications properly as prescribed by their doctor, which costs the nation more than $290 billion annually in avoidable health spending annually, citing policy research group NEHI. “Pharmacists are widely trusted healthcare professionals with extensive education," stated Steve Anderson, NACDS president and CEO. "They are trained medication specialists who work collaboratively to help patients use medicines safely and stay healthy,” he said. “This legislation will go a long way in helping to further pharmacists’ ability to help improve patient health and make health care more affordable.”
Currently Medicare Part D Plans are only required to offer MTM coverage plans to beneficiaries with multiple chronic conditions. The MTM Empowerment Act allows seniors with only one high cost chronic condition, such as diabetes, hypertension or asthma to access MTM services.
The bill includes safeguards to ensure that expanding access to MTM in Medicare will not increase spending but actually save money. Language in the bill stipulates that before seniors with one high-cost chronic condition may see a qualified provider for a comprehensive medication review, the Chief Actuary at the Centers for Medicare and Medicaid Services must certify that the program will lower spending. And, five years after implementation, the Chief Actuary must certify that the program actually did lower spending. Although all current evidence indicates that increased access to MTM services lowers overall health care spending for participating patients, if the Chief Actuary finds that the program did not lower spending, then the Secretary of Health and Human Services must review whether to continue the program for seniors with one high-cost chronic condition.
No comments found
Reports: FDA generic drug chief resigns
NEW YORK — The director of the Food and Drug Administration’s Office of Generic Drugs is stepping down, according to published reports.
Pharmalot, a blog run by journalist Ed Silverman, reported that Greg Geba is leaving the office over differences resulting from a recent reorganization, effective Friday.
In his resignation letter, Geba wrote that the OGD has issued almost 600 complete response letters and approved nearly 200 generic drug applications since the Oct. 1 implementation of the Generic Drug User Fee Amendments.
The Generic Pharmaceutical Association, an industry trade group, expressed concerns that Geba’s departure could lead to "further disruption" at the OGD in the wake of the office having no leader from 2010 to 2012.
"GPhA was disappointed to learn of Dr. Gregory Geba’s departure from the FDA’s Office of Generic Drugs," GPhA president and CEO Ralph Neas said. "Today, 80% of prescriptions dispensed in America are generics. GPhA and its member companies rely on the strength and continuity of the OGD on critical matters such as regulations governing the entry to market of new, cost-saving generic versions of critical medicines, and the implementation of the GDUFA process."
The policies of government associated with not letting generic medicines into market has produce a problems for patients. The brand called drugs are available for hefty costs whereas generic drugs are accessible very cheap. For instance, drugs with regard to sexual pleasure are not included in to healthcare plan, so guys have to pay extra fortune for this. If these drugs are accessible cheap, its good for individuals. So instead of purchasing Pfizer's Inch The Viagra , they can try universal drugs containing Forzest.
Alberta pharmacist group ‘shocked’ at planned generic drug price reductions
EDMONTON, Alberta — A plan to significantly reduce generic drug prices in Alberta has drawn criticism from pharmacists in the Canadian province.
The Alberta Pharmacists’ Association said it was "shocked" in response to the provincial government’s 2013 budget, which reduces generic drug prices from 35% to 18% of branded drug prices, effective May 1. Over the past two years, prices have been reduced from 75% to 35%, but the RxA said it supported the government in those cases.
"The cuts are so deep and so fast, it will be impossible for me to react quickly enough to ensure the sustainability of my pharmacy," Rimby, Alberta, pharmacist Patrick Rurka said on behalf of the group. "My patients and community will be the real losers as the health services my pharmacy offers will be compromised. The patients’ needs will either be off-loaded to physicians or will be left untreated."
No comments found